Last reviewed:
Check the missed-dose instructions for your exact HIV medicine. Many daily tablets should be taken when remembered unless the next dose is close; do not take a double dose to make up for a missed one. Keep any meal requirement. If you are unsure, cannot keep medication down, have run out, or may miss an injection appointment, contact your pharmacist or HIV care team promptly.[3][4][5][6][9]
The general rule
MedlinePlus gives the take-when-remembered, skip-if-near-the-next-dose instruction for Dovato, Odefsey and Symtuza. Its Biktarvy entry says to take the missed dose when remembered and not double it. Follow the instructions supplied for your exact product; if the timing is unclear, a pharmacist can help. Taking medicines as prescribed and getting support for missed doses are part of HIV treatment adherence.[3][5][6][4][7]
If your tablet requires food, a late dose still needs the required meal or food. If you vomit after a dose, call your pharmacist or clinic with the medication name and time taken. Whether another dose is appropriate depends on the product and circumstances; do not automatically repeat it based on a universal two- or four-hour rule. If you cannot keep medicines or fluids down, seek prompt medical advice.[2][5][7]
What your specific regimen says
- Biktarvy (bictegravir/emtricitabine/TAF) — “Take the missed dose as soon as you remember it. Do not take a double dose to make up for a missed one.” Taken with or without food[3]
- Dovato (dolutegravir/lamivudine) — take the missed dose as soon as you remember; if it is almost time for the next dose, skip it and continue your schedule; no double dose. Taken with or without food[4]
- Odefsey (emtricitabine/rilpivirine/TAF) — same missed-dose rule, and the medicine must be taken with food (a meal) once a day, so a late dose needs a meal with it[5]
- Symtuza (darunavir/cobicistat/emtricitabine/TAF) — same missed-dose rule; taken with food once a day[6]
- Long-acting injections (Cabenuva) — contact your clinic if you will miss the target injection date by more than seven days. A prescribed oral regimen may bridge the gap. Oral cabotegravir plus rilpivirine can be used for up to two months; another fully suppressive oral regimen is also an option. The start date and injection restart doses depend on whether your schedule is monthly or every two months and the time since the last injections.[9]
These examples do not cover every HIV medication. Do not use another person’s missed-dose instructions for your regimen. Ask your pharmacist to write down what to do if you are late or miss a dose.
What a missed dose can mean
One missed dose does not by itself tell you that treatment has failed, but there is no universally safe number of missed doses. The effect depends on your regimen, resistance history, viral suppression and the pattern of missed doses. NIH recommends considering medicines with high resistance barriers when adherence has been difficult. Missed long-acting injections also require a timely plan because falling drug levels can allow viral rebound and resistance.[9][8]
NIH identifies dolutegravir-, bictegravir- and boosted darunavir-based regimens as having high barriers to resistance. For U=U, the key is maintaining a viral load below 200 copies/mL on treatment: sustained suppression prevents sexual transmission. The minimum adherence needed to maintain that protection has not been established for every regimen. Poor adherence or an interruption can allow rebound, so discuss additional prevention and viral-load testing if suppression is uncertain.[11][12][1]
Longer gaps: what actually happens, and how to restart
After stopping ART, viral rebound can occur within days to weeks. NIH advises against planned interruptions outside research and recommends minimizing unavoidable gaps. Its instructions to hold and restart regimen components together describe clinician-managed situations such as inability to take medicines by any enteral route; they are not permission to take medication holidays. Severe or life-threatening toxicity requires a different complete regimen without the offending medicine after recovery, under medical supervision.[12][1][2]
If you have been off treatment, contact your HIV team promptly to make a restart plan. Explain why you stopped, which drugs you took and any previous reactions. Your clinician may check viral load, resistance and other health issues before selecting or confirming the regimen. A general time-to-suppression estimate after initial therapy cannot predict your own response after an interruption.[1]
Missed doses are usually a systems problem — and when to call
NIH recommends that clinicians ask about adherence at every visit in a constructive, nonjudgmental way. Accurate information about missed doses helps them identify obstacles and work with you on practical solutions. You deserve help with the problem, rather than blame.[1]
Barriers can include stigma, unstable housing, cost, transportation, depression, food insecurity, privacy concerns, pill fatigue and pharmacy problems. Support may include reminders, delivery, refill coordination, case management, mental-health care, financial assistance or a simpler regimen. Long-acting treatment is appropriate only when its clinical requirements and a reliable injection plan can be met; it is not an automatic solution for every adherence problem.[1]
Call promptly if you run out or expect to run out, miss several doses, cannot keep medication down, or have a cost, insurance, transportation or housing barrier. For Cabenuva, contact the clinic before an appointment is more than seven days outside its target date. Do not wait for an arbitrary number of days off treatment before asking for help, and do not ration or alter doses without a pharmacist or clinician’s instructions.[7][2][9]
Florida: if the barrier is access, not memory
HHS names AIDS Drug Assistance Programs and Ryan White HIV/AIDS Program services as adherence interventions in their own right, and tells clinicians to make and review a plan for uninterrupted access to treatment with every person living with HIV[1]. In Florida, that plan has phone numbers: the ADAP Help Desk at 844-381-2327, direct medication services through Prime Therapeutics at 833-604-0925, and enrollment through your county health department. If you do not qualify for ADAP, pharmaceutical patient assistance programs, the Patient Advocate Foundation Co-Pay Relief program, and HarborPath are the next doors to knock on[10].
One gentle Florida-specific note: formulary and income-eligibility rules shifted more than once during 2026 — Florida DOH confirms Biktarvy was restored to the ADAP formulary on July 1, 2026, along with Descovy[10]. If a refill was denied or your coverage changed without warning, you are not imagining it and it is not your fault. Call ADAP or your case manager rather than rationing what you have left.
Related questions
Should I take two pills if I forgot yesterday's dose?
Will one missed dose make me detectable or cause resistance?
A missed dose alone does not establish treatment failure. Risk depends on the regimen, resistance, viral suppression and how often doses are missed. There is no universally safe missed-dose allowance. Follow your medication’s instructions, and ask your care team for help if missed doses repeat or an injection visit may be delayed.[8][9][12]
What if I have been off my medication for weeks?
Contact your HIV care team promptly for a restart plan. Tell them how long you have been off treatment and why, especially if you stopped because of a serious reaction. They can determine the appropriate regimen and any viral-load or resistance tests. Do not assume that a fixed number of weeks guarantees suppression after restarting.[2][11]
Do I have to tell my provider I missed doses?
Yes. NIH recommends constructive, nonjudgmental adherence discussions at every visit. Honest information helps your team address barriers and choose practical support. That recommendation is about the quality of care; it is not a guarantee that visits have no charge.[11]
Related from RiseUpToHIV
References & Sources
- HHS/NIH — Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (adherence section, full PDF). Nonjudgmental adherence assessment language, resistance barriers, viral rebound timing, named barriers and interventions, and suppression timelines. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
- HHS/NIH — Discontinuation or Interruption of Antiretroviral Therapy. Why planned interruptions are not recommended, holding a regimen for short gaps, and stopping or restarting oral components together. ↩ ↩ ↩ ↩
- NIH MedlinePlus — Bictegravir, Emtricitabine, and Tenofovir Alafenamide (Biktarvy). Verbatim missed-dose instruction and food information for Biktarvy. ↩ ↩ ↩ ↩
- NIH MedlinePlus — Dolutegravir and Lamivudine (Dovato). Missed-dose instruction, including the skip-if-close rule, and food information. ↩ ↩ ↩ ↩
- NIH MedlinePlus — Emtricitabine, Rilpivirine, and Tenofovir Alafenamide (Odefsey). Missed-dose instruction plus the requirement to take Odefsey with a meal. ↩ ↩ ↩ ↩ ↩
- NIH MedlinePlus — Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (Symtuza). Missed-dose instruction and the with-food requirement for Symtuza. ↩ ↩ ↩ ↩
- NIH HIVinfo — HIV Treatment Adherence: taking medicines as prescribed and getting help with barriers. Source. ↩↩↩
- NIH — Adherence to the Continuum of Care: regimen selection, resistance barriers and individualized support. Source. ↩ ↩
- FDA — Cabenuva prescribing information (missed-injection management). Oral bridging for planned gaps and re-initiation rules for unplanned gaps in long-acting therapy. ↩ ↩ ↩ ↩ ↩
- Florida Department of Health — AIDS Drug Assistance Program. ADAP Help Desk and Prime Therapeutics numbers, alternative assistance programs, and the July 1, 2026 Biktarvy restoration. ↩ ↩
- NIH — Adherence to the Continuum of Care. Source. Checked September 21, 2026. ↩ ↩ ↩
- NIH — Antiretroviral Therapy to Prevent Sexual Transmission: suppression below 200 copies/mL, adherence and interruption risk. Source. Checked September 21, 2026. ↩ ↩ ↩
Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.